 |
|
Treatment of Postmenopausal Hyperparathyroidism With NorethindroneLong-term Effects on Forearm Mineral Content
Judith Wishart;
Michael Horowitz, PhD, FRACP;
Allan Need, MD, FRACP;
Barry Chatterton, FRACP;
B. E. Christopher Nordin, DSc, FRACP
Arch Intern Med. 1990;150(9):1951-1953.
Abstract
• In 15 postmenopausal women with mild primary hyperparathyroidism, the long-term effect of norethindrone therapy (5 mg/d) on forearm bone mineral content (FMC) was evaluated. The FMC rose from 810 ± 39 (SEM) mg/cm at baseline to 841 ± 41 mg/cm after 2 years of treatment, representing a mean bone mineral gain of 1.9% per year. The majority of this bone gain occurred during the first 6 months of treatment. The rate of increase in FMC in the first 6 months was ± 3.71 ± 0.12mg/cm per month compared with -0.35 ±0.51 mg/cm per month during the second year. Fat-corrected FMC was measured to determine whether the bone gain was real or reflected a decrease in fat mass. There was a similar rise in fat-corrected FMC (from 885 ± 36 mg/cm at baseline to 909±39 mg/cm at 2 years). The difference between fat-corrected and uncorrected FMC, however, decreased slightly on norethindrone treatment (from 75.2 ±11.9 mg/cm at baseline to 67.8 ±11.8 mg/cm at 12 months), indicating a reduction in the subcutaneous fat layer. We conclude that norethindrone therapy in postmenopausal women with mild primary hyperparathyroidism produces a gain in bone mass that is sustained for at least 2 years.
(Arch Intern Med. 1990;150:1951-1953)
Author Affiliations
From the Departments of Medicine (Ms Wishart and Dr Horowitz) and Nuclear Medicine (Dr Chatterton), Royal Adelaide Hospital, and the Division of Clinical Chemistry, Institute of Medical and Veterinary Science (Drs Need and Nordin), Adelaide, South Australia, Australia.
Footnotes
Accepted for publication March 13,1990.
Reprint requests to Department of Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000, Australia (Ms Wishart).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism
Reppe et al.
Am. J. Physiol. Endocrinol. Metab. 2007;292:E1465-E1473.
ABSTRACT
| FULL TEXT
|
